Claims for Patent: 5,480,640
✉ Email this page to a colleague
Summary for Patent: 5,480,640
Title: | Alpha interferon for treating prostate cancer |
Abstract: | Described is a method for treating carcinoma of the prostate using recombinant human alpha interferon via intraprostatic or intralesional injection. |
Inventor(s): | Morales; Alvaro (Kingston, CA), Wilson; James W. L. (Kingston, CA) |
Assignee: | Schering Corporation (Kenilworth, NJ) |
Application Number: | 08/432,742 |
Patent Claims: | 1. A method for treating cancer of the prostate comprising administering a therapeutically effective amount of alpha interferon by intraprostatic or intralesional injection.
2. The method of claim 1 wherein the alpha interferon is administered by intraprostatic injection such that the whole prostate is infiltrated. 3. The method of claim 1 wherein the alpha interferon is administered by intralesional injection such that the entire lesion is infiltrated. 4. The method of claim 1 wherein the alpha interferon is selected from interferon alfa-2a, interferon alfa-2b, interferon alfa-2c, interferon alfa-n 1, consensus alfa interferon, and interferon alfa-n3. 5. The method of claim 4 wherein the alpha interferon is interferon alfa-2b. 6. The method of clam 5 wherein the interferon alfa-2b is administered once per week for a period of 5 weeks in progressively increasing dosages. 7. The method of claim 6 wherein the increasing dosages are 1.times.10.sup.6, 2.times.10.sup.6, 3.times.10.sup.6, 4.times.10.sup.6, and 5.times.10.sup.6 I.U. |
Details for Patent 5,480,640
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Merck Sharp & Dohme Corp. | INTRON A | interferon alfa-2b | For Injection | 103132 | 06/04/1986 | ⤷ Try a Trial | 2039-03-29 |
Merck Sharp & Dohme Corp. | INTRON A | interferon alfa-2b | For Injection | 103132 | ⤷ Try a Trial | 2039-03-29 | |
Merck Sharp & Dohme Corp. | INTRON A | interferon alfa-2b | Injection | 103132 | ⤷ Try a Trial | 2039-03-29 | |
Hemispherx Biopharma, Inc. | ALFERON N INJECTION | interferon alfa-n3 (human leukocyte derived) | Injection | 103158 | 10/10/1989 | ⤷ Try a Trial | 2039-03-29 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.